Nov 29 (Reuters) - Immutep Ltd (IMM) :
- IMMUTEP ENTERS INTO SECOND CLINICAL TRIAL COLLABORATION AGREEMENT WITH MERCK KGAA, DARMSTADT, GERMANY, AND PFIZER FOR NEW COMBINATION STUDY OF ITS FIRST-IN-CLASS LAG-3 CANDIDATE, EFTILAGIMOD ALPHA, AND AVELUMAB TO TREAT UROTHELIAL CANCER
- IMMUTEP ENTERS INTO SECOND CLINICAL TRIAL COLLABORATION AGREEMENT WITH MERCK KGAA, DARMSTADT, GERMANY, AND PFIZER FOR NEW COMBINATION STUDY OF ITS FIRST-IN-CLASS LAG-3 CANDIDATE, EFTILAGIMOD ALPHA, AND AVELUMAB TO TREAT UROTHELIAL CANCER
- IMMUTEP LTD - FIRST PATIENT IS EXPECTED TO BE ENROLLED AND DOSED IN H1 OF CALENDAR YEAR 2023
- IMMUTEP LTD - UNDER AGREEMENT, IMMUTEP AND MERCK KGAA, DARMSTADT, GERMANY WILL JOINTLY FUND INSIGHT-005 STUDY
News: IMM Immutep Enters Into Second Clinical Trial Collaboration Agreement With Merck KGaA,...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
25.0¢ |
Change
-0.010(3.85%) |
Mkt cap ! $366.9M | |||
| Open | High | Low | Value | Volume |
| 26.0¢ | 26.0¢ | 24.8¢ | $253.0K | 1.008M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 10 | 119907 | 25.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 25.5¢ | 717012 | 52 |
View Market Depth
| Last trade - 15.03pm 16/09/2025 (20 minute delay) ? |
| IMM (ASX) Chart |